Pharmaceutical Non-Active Ingredients TRIZ Cases

Peptide amphiphile nanoparticles self-assemble into micelles that localize anti-inflammatory drugs at inflamed tissue sites, reducing systemic side effects.

A lactic acid-glycolic acid copolymer solution undergoes controlled precipitation to yield a purified powder form.

Composite lipid ratios and net negative charge resolve low encapsulation efficiency of vinca alkaloids in conventional liposomes.

Segmented saponin conjugates improve endosomal escape to reduce off-target toxicity while maintaining high therapeutic efficacy.

Incorporating 2-morpholinoethanesulfonic acid buffers pH fluctuations, preventing phospholipid hydrolysis and oxaliplatin degradation during long-term storage.

IgG4 antibody drug conjugates resolve chemical instability and agonist toxicity by modifying the antibody isotype for stable targeted delivery.

Combining non-swelling pH-dependent and pH-independent retardants achieves reproducible, pH-independent drug release while minimizing swelling variability.

Shear-thinning pectic acid hydrogel resolves the trade-off between structure fidelity and cell viability during injection.

A halogen-resistant film composition uses polyvinyl alcohol blended with protective agents to maintain structural integrity.

A soft capsule film composition combines native gellan gum with hydrophilic polysaccharides, starch, and a plasticizer to enhance mechanical strength.

Electron-withdrawing substituents protect the tubulysin acetate group from hydrolytic cleavage, preserving biological activity in ADC formulations.

A biopolymer scaffold compound with peptide n-mers selectively binds and depletes undesirable antibodies from patient circulation.

Segmented recognition moieties guide reactive groups to target proteins, preserving native activity while enabling selective labeling.

Unconjugated bile acids trigger receptor aggregation to enable intracellular uptake, avoiding cytotoxicity from cationic lipids.

Tetrazine antibody conjugates enable selective payload localization via bioorthogonal click reactions.

Hydrophobic ligands enhance plasma protein binding of nucleic acid conjugates to overcome limited extrahepatic tissue distribution.

Conjugating Siglec ligands to antibodies recruits inhibitory Siglecs to suppress mast cell and B cell activation, reducing allergic responses.

Optimized excipient ratios achieve disintegration in under ten seconds, resolving the trade-off between mechanical stability and rapid absorption.

A uPAR-targeting conjugate with a tailored linker group and molecular size under 50 kDa achieves rapid tumor accumulation.

Aromatic polycarbonate resin blends with bromine-substituted carbonate oligomer and phosphorus compounds to create flame resistant materials.

A non-reducing end-modified glucan binds N-acetylglucosamine residues to enhance immune stimulation.

A multifunctionalized polycaprolactone polymer incorporates amino and hydroxyl groups directly into the backbone during ring-opening polymerization.

Pyrroplus granulation transforms crystalline active ingredients into amorphous states using 2-pyrrolidone and silicon dioxide.

An antibody modified with a hydrophilic polymer block and cleavable bond reduces off-target binding while restoring activity in specific tissues.

Peptide conjugates transport SN38 across the blood-brain barrier, solving water solubility and stability issues in aqueous solutions.

Maleimido-functionalized polymer spacers decouple high drug load from antibody binding affinity and in vivo clearance rates.

Methacrylic acid copolymer masks ibuprofen bitterness, enabling 15-minute oral retention for sustained pain relief.

Segmented PEG linkers maintain storage stability while enabling controlled payload release via dynamic cleavage.

A heterobifunctional monodispersed polyethylene glycol linker joins antibodies and drugs via stable ether bonds.

Formulations using lipid and surfactant carriers stabilize nanoparticles against precipitation in hot aqueous liquids, resolving solubility trade-offs.

Circular polyribonucleotides recruit E3 ubiquitin ligases to degrade stable pathogenic proteins that resist conventional treatment.

Acid-type carboxymethylcellulose and crystalline cellulose form a composite disintegrative particulate composition for orally disintegrating tablets.

Boronic acid-containing polymers deliver therapeutic agents via cis-diol binding, resolving insufficient targeted delivery capability in conventional hydrogels.

Spray aqueous biopolymer solutions with carbon dioxide and co-solvents to generate dry micro- and nano-sized particles.

A branched hetero polyethylene glycol compound features multiple arms radiating from a central core to modify bio-functional molecules.

Aqueous esterified cellulose ether dispersions enable stable high-concentration film formation.

Synthetic antigen-lipid constructs partition into plasma to neutralize circulating antibodies via intravenous infusion.

Poly epsilon-caprolactone-ethoxylated fatty acid block copolymers self-assemble into stable nanocarriers.

Segmented manufacturing separates film formation from drug loading, overcoming low capacity limits in conventional oral films.

Carrier pellets use spray granulation to form spherical units with controlled pH, resolving coating faults that cause uncontrolled drug release.

Palmitoyl chitosan forms a pH-responsive hydrogel that solves the trade-off between injectability and long-term release duration.

Tumor-homing artemisinin derivatives conjugate cytotoxic agents with heptamethine carbocyanine dyes to overcome drug resistance and reduce side effects.

A water-soluble polymer conjugated with amino acid oligopeptides and drug molecules increases drug load capacity.

Click chemistry bonds gadolinium agents to capture substrates, reducing tissue accumulation in patients with reduced renal function.